Japan's Takeda Pharmaceutical has carried out a major management reshuffle. Under the reorganization: Shigenori Ohkawa will become chief scientific officer and his role as general manager of the pharmaceutical research division will be assumed by Hiroyuki Odaka; former chief executive of Takeda North America Alan MacKenzie is now executive vice president of international operations and will be replaced by Shinji Honda; Tetsuo Miwa was promoted to general manager of the company's chemistry manufacturing controls center; and Nancy Joseph-Ridge takes over from Masaomi Miyamoto as general manager of the pharmaceutical development division. Additionally, the firm is to appoint a chief administrative officer at a later date.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze